Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D.

Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.

PMID:
24297376
2.

A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients.

Nair SC, Welsing PM, Choi IY, Roth J, Holzinger D, Bijlsma JW, van Laar JM, Gerlag DM, Lafeber FP, Tak PP.

PLoS One. 2016 Mar 30;11(3):e0152362. doi: 10.1371/journal.pone.0152362. eCollection 2016.

3.

From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis.

Choi IY, Gerlag DM, Holzinger D, Roth J, Tak PP.

PLoS One. 2014 Aug 28;9(8):e106253. doi: 10.1371/journal.pone.0106253. eCollection 2014.

4.

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.

Anink J, Van Suijlekom-Smit LW, Otten MH, Prince FH, van Rossum MA, Dolman KM, Hoppenreijs EP, ten Cate R, Ursu S, Wedderburn LR, Horneff G, Frosch M, Vogl T, Gohar F, Foell D, Roth J, Holzinger D.

Arthritis Res Ther. 2015 Aug 7;17:200. doi: 10.1186/s13075-015-0723-1.

5.

Myeloid-related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate.

Patro PS, Singh A, Misra R, Aggarwal A.

J Rheumatol. 2016 Apr;43(4):731-7. doi: 10.3899/jrheum.150998. Epub 2016 Feb 1.

PMID:
26834220
6.

Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.

Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.

J Rheumatol. 2011 Nov;38(11):2346-54. doi: 10.3899/jrheum.101295. Epub 2011 Oct 1.

PMID:
21965648
7.

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis.

Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, ten Cate R, Hoppenreijs EP, Hansmann S, Moncrieffe H, Ursu S, Wedderburn LR, Roth J, Foell D, Wittkowski H.

Ann Rheum Dis. 2012 Jun;71(6):974-80. doi: 10.1136/annrheumdis-2011-200598. Epub 2012 Jan 20.

PMID:
22267331
8.

Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.

Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.

Rheumatology (Oxford). 2008 Jun;47(6):780-8. doi: 10.1093/rheumatology/ken083. Epub 2008 Apr 3.

PMID:
18388148
9.

Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.

Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.

Rheumatology (Oxford). 2007 Mar;46(3):446-53. Epub 2006 Aug 9.

PMID:
16899502
10.

CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.

Stuhlmüller B, Häupl T, Hernandez MM, Grützkau A, Kuban RJ, Tandon N, Voss JW, Salfeld J, Kinne RW, Burmester GR.

Clin Pharmacol Ther. 2010 Mar;87(3):311-21. doi: 10.1038/clpt.2009.244. Epub 2009 Dec 23.

PMID:
20032971
11.

Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.

Ajeganova S, Fiskesund R, de Faire U, Hafström I, Frostegård J.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):942-50. Epub 2011 Dec 22.

PMID:
22153361
12.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.

13.

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.

14.

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.

Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K.

Ann Rheum Dis. 2009 Nov;68(11):1739-45. doi: 10.1136/ard.2008.092833. Epub 2008 Nov 19.

PMID:
19019895
15.

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.

Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.

Ann Rheum Dis. 2005 May;64(5):704-7. Epub 2004 Oct 14.

16.

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.

Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C; Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.

Arthritis Rheum. 2007 May;56(5):1417-23.

17.

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.

Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BA, Nurmohamed MT.

J Rheumatol. 2008 Oct;35(10):1972-7. Epub 2008 Sep 1.

PMID:
18785316
18.

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.

Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL.

Arthritis Res Ther. 2011 Jul 30;13(4):R126. doi: 10.1186/ar3431.

19.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
20.

The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.

Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S.

Arthritis Rheum. 2013 Jan;65(1):88-97. doi: 10.1002/art.37707.

Supplemental Content

Support Center